Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.
Moderna has reported that its Covid-19 vaccine candidate, mRNA-1273, induced immune responses in older adults in a Phase I clinical trial, indicating its potential for use across age groups.
Last month, the vaccine candidate was found to be safe and effective in Phase I participants aged 18-55 years.
The latest results are from an analysis of 20 additional older volunteers who were given a 100μg dose. According to the company, the immune response was similar across age groups of 56 to 70, above 70 and 18 to 55 years.
Data showed that the older adults’ antibody levels were two to three times higher than those found in patients who had recovered from Covid-19.
The company has completed participant enrolment for both cohorts in the Phase II trial of the vaccine candidate, involving subjects aged 18-55, and aged 55 and above.
This Phase II trial is assessing the safety, reactogenicity and immunogenicity of two vaccinations of 50μg or 100μg doses of mRNA-1273 administered 28 days apart.
Moderna has also started dosing participants in the Phase III trial of the Covid-19 vaccine candidate.
The Phase III study, called COVE, is being run in alliance with the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).
It is designed to evaluate a 100µg dose of the vaccine candidate in around 30,000 participants in the US.
So far, the company enroled more than 13,000 participants, of which 18% are Black, Latino, Native American or Alaska Native groups, reported Reuters.
Moderna received nearly $1bn from the US Government under its Operation Warp Speed programme and also signed a $1.5bn agreement to supply in the country.